{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T19:47:40Z","timestamp":1783108060530,"version":"3.54.6"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Increasing numbers of trans and gender diverse young people are presenting to health services seeking gender-affirming medical care. While testosterone therapy in transgender males is generally effective in inducing masculinization, some adolescents encounter barriers to accessing such treatment or may not wish to experience all the changes that usually accompany testosterone. Here, we describe the case of a 17 year old trans male who presented with gender dysphoria but was initially unable to start testosterone therapy. Due to a desire for facial hair, he was therefore treated with topical minoxidil, an easily accessible, over-the-counter medication that has been used to treat androgenic alopecia for several decades. In this case, minoxidil was applied regularly to the lower face and, after three months of treatment, he developed obvious pigmented facial hair that was sufficient to help him avoid being misgendered. The only reported side effect was excessive skin dryness. Unexpectedly, despite no direct application to other areas, there was also an increase in pigmented body hair, suggestive of systemic absorption and effect. Given its long-standing use and safety record in the management of alopecia, minoxidil might thus represent a useful treatment option for trans males who desire an increase in facial hair.<\/jats:p>","DOI":"10.3389\/fendo.2021.725269","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T07:27:46Z","timestamp":1632900466000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Case Report: Successful Use of Minoxidil to Promote Facial Hair Growth in an Adolescent Transgender Male"],"prefix":"10.3389","volume":"12","author":[{"given":"Kenneth C.","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Upreti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2013.11.008","article-title":"The Health and Well-Being of Transgender High School Students: Results From the New Zealand Adolescent Health Survey (Youth'12)","volume":"55","author":"Clark","year":"2014","journal-title":"J Adolesc Health"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1089\/lgbt.2017.0176","article-title":"Perceived Gender Presentation Among Transgender and Gender Diverse Youth: Approaches to Analysis and Associations With Bullying Victimization and Emotional Distress","volume":"5","author":"Gower","year":"2018","journal-title":"LGBT Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1089\/lgbt.2019.0232","article-title":"Mental Health Issues and Complex Experiences of Abuse Among Trans and Gender Diverse Young People: Findings From Trans Pathways","volume":"7","author":"Strauss","year":"2020","journal-title":"LGBT Health"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2016.06.012","article-title":"The Mental Health of Transgender Youth: Advances in Understanding","volume":"59","author":"Connolly","year":"2016","journal-title":"J Adolesc Health"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2017.04.014","article-title":"Risk and Protective Factors in the Lives of Transgender\/Gender Nonconforming Adolescents","volume":"61","author":"Eisenberg","year":"2017","journal-title":"J Adolesc Health"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2017.06.010","article-title":"Prevalence and Correlates of Suicidal Ideation Among Transgender Youth in California: Findings From a Representative, Population-Based Sample of High School Students","volume":"56","author":"Perez-Brumer","year":"2017","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.5694\/mja17.01044","article-title":"Australian Standards of Care and Treatment Guidelines for Transgender and Gender Diverse Children and Adolescents","volume":"209","author":"Telfer","year":"2018","journal-title":"Med J Aust"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2019.03.406","article-title":"The Contemporary Sex Ratio of Transgender Youth That Favors Assigned Females at Birth Is a Robust Phenomenon: A Response to the Letter to the Editor Re: \"Shifts in Assigned Sex Ratios at Gender Identity Clinics Likely Reflect Change in Referral Patterns\"","volume":"16","author":"Zucker","year":"2019","journal-title":"J\u00a0Sex Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jsm.12817","article-title":"Evidence for an Altered Sex Ratio in Clinic-Referred Adolescents With Gender Dysphoria","volume":"12","author":"Aitken","year":"2015","journal-title":"J Sex Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02231","article-title":"Clinical Management of Gender Identity Disorder in Adolescents: A Protocol on Psychological and Paediatric Endocrinology Aspects","volume":"155","author":"Delemarre van de Waal","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine Treatment of Gender-Dysphoric\/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.36468\/pharmaceutical-sciences.spl.139","article-title":"Review of Topical Therapies for Beard Enhancement","volume":"82","author":"Almurayshid","year":"2020","journal-title":"Indian J Pharm Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/09546630701567378","article-title":"A Randomized, Double-Blind, Controlled Trial of Testosterone Gel Treatment Versus Vehicle Control on the Facial Hair of Young Men With Beta-Thalassemia Major","volume":"18","author":"Saeedi","year":"2007","journal-title":"J\u00a0Dermatolog Treat"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13312","article-title":"Efficacy and Safety of Minoxidil 3% Lotion for Beard Enhancement: A Randomized, Double-Masked, Placebo-Controlled Study","volume":"43","author":"Ingprasert","year":"2016","journal-title":"J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198010163031607","article-title":"Minoxidil and the Treatment of Severe Hypertension","volume":"303","author":"Pettinger","year":"1980","journal-title":"N Engl J\u00a0Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2004.03585.x","article-title":"Minoxidil: An Underused Vasodilator for Resistant or Severe Hypertension","volume":"6","author":"Sica","year":"2004","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(87)80003-8","article-title":"Topical Minoxidil Solution (1% and 5%) in the Treatment of Alopecia Areata","volume":"16","author":"Fiedler-Weiss","year":"1987","journal-title":"J Am Acad Dermatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.06.014","article-title":"A Randomized, Placebo-Controlled Trial of 5% and 2% Topical Minoxidil Solutions in the Treatment of Female Pattern Hair Loss","volume":"50","author":"Lucky","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2002.124088","article-title":"A Randomized Clinical Trial of 5% Topical Minoxidil Versus 2% Topical Minoxidil and Placebo in the Treatment of Androgenetic Alopecia in Men","volume":"47","author":"Olsen","year":"2002","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.04.012","article-title":"A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of a Novel Formulation of 5% Minoxidil Topical Foam Versus Placebo in the Treatment of Androgenetic Alopecia in Men","volume":"57","author":"Olsen","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.05785.x","article-title":"Minoxidil: Mechanisms of Action on Hair Growth","volume":"150","author":"Messenger","year":"2004","journal-title":"Br J Dermatol"},{"key":"B22","article-title":"Mechanism of Action of Minoxidil in the Treatment of Androgenetic Alopecia Is Likely Mediated by Mitochondrial Adenosine Triphosphate Synthase-Induced Stem Cell Differentiation","volume":"31","author":"Goren","year":"2017","journal-title":"J Biol regulators homeostatic Agents"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000096924","article-title":"Topical Use of Minoxidil in Children and Systemic Side Effects","volume":"214","author":"Georgala","year":"2007","journal-title":"Dermatol (Basel Switzerland)"},{"key":"B24","unstructured":"OakleyA\n          Minoxidil Solution1998"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.725269\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T07:27:50Z","timestamp":1632900470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.725269\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":24,"alternative-id":["10.3389\/fendo.2021.725269"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.725269","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"article-number":"725269"}}